The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of pemetrexed plus cisplatin versus pemetrexed plus carboplatin in the initial treatment of locally advanced or metastatic non-small cell lung cancer.
A. A. R. Pereira
No relevant relationships to disclose
R. C. Lessa
No relevant relationships to disclose
C. E. P. Souza
No relevant relationships to disclose
F. A. I. Pinto
No relevant relationships to disclose
D. M. Gagliato
No relevant relationships to disclose
E. S. Santos
No relevant relationships to disclose
M. F. Fanelli
No relevant relationships to disclose
J. A. Rinck
No relevant relationships to disclose
A. A. Dettino
No relevant relationships to disclose
U. R. Nicolau
No relevant relationships to disclose
L. T. D. Chinen
No relevant relationships to disclose
V. C. C. de Lima
No relevant relationships to disclose
J. R. Pereira
No relevant relationships to disclose
M. R. D. S. Cruz
No relevant relationships to disclose